227 related articles for article (PubMed ID: 38396493)
1. Enhancing Cervical Cancer Screening: Review of p16/Ki-67 Dual Staining as a Promising Triage Strategy.
Ouh YT; Kim HY; Yi KW; Lee NW; Kim HJ; Min KJ
Diagnostics (Basel); 2024 Feb; 14(4):. PubMed ID: 38396493
[TBL] [Abstract][Full Text] [Related]
2. P16/Ki-67 Dual Staining in Positive Human Papillomavirus DNA Testing for Predictive Diagnosis of Abnormal Cervical Lesions in Northeastern Thai Women.
Aromseree S; Wongjumpa W; Ekalaksananan T; Temtanakitpaisan A; Kleebkaow P; Srisathaporn S; Tongchai P; Pientong C
Asian Pac J Cancer Prev; 2022 Oct; 23(10):3405-3411. PubMed ID: 36308365
[TBL] [Abstract][Full Text] [Related]
3. Triaging HPV-positive women with normal cytology by p16/Ki-67 dual-stained cytology testing: baseline and longitudinal data.
Uijterwaal MH; Polman NJ; Witte BI; van Kemenade FJ; Rijkaart D; Berkhof J; Balfoort-van der Meij GA; Ridder R; Snijders PJ; Meijer CJ
Int J Cancer; 2015 May; 136(10):2361-8. PubMed ID: 25345358
[TBL] [Abstract][Full Text] [Related]
4. Five-Year Risk of Cervical Precancer Following p16/Ki-67 Dual-Stain Triage of HPV-Positive Women.
Clarke MA; Cheung LC; Castle PE; Schiffman M; Tokugawa D; Poitras N; Lorey T; Kinney W; Wentzensen N
JAMA Oncol; 2019 Feb; 5(2):181-186. PubMed ID: 30325982
[TBL] [Abstract][Full Text] [Related]
5. Triaging Pap cytology negative, HPV positive cervical cancer screening results with p16/Ki-67 Dual-stained cytology.
Petry KU; Schmidt D; Scherbring S; Luyten A; Reinecke-Lüthge A; Bergeron C; Kommoss F; Löning T; Ordi J; Regauer S; Ridder R
Gynecol Oncol; 2011 Jun; 121(3):505-9. PubMed ID: 21420158
[TBL] [Abstract][Full Text] [Related]
6. Clinical value of fully automated p16/Ki-67 dual staining in the triage of HPV-positive women in the Norwegian Cervical Cancer Screening Program.
Ovestad IT; Dalen I; Hansen E; Loge JL; Dybdahl BM; Dirdal MB; Moltu P; Berland JM
Cancer Cytopathol; 2017 Apr; 125(4):283-291. PubMed ID: 27918650
[TBL] [Abstract][Full Text] [Related]
7. Performance of P16/Ki67 dual staining in triaging hr-HPV-positive population during cervical Cancer screening in the younger women.
Qian QP; Zhang X; Ding B; Jiang SW; Li ZM; Ren ML; Shen Y
Clin Chim Acta; 2018 Aug; 483():281-285. PubMed ID: 29758205
[TBL] [Abstract][Full Text] [Related]
8. p16/Ki67 dual staining improves the detection specificity of high-grade cervical lesions.
Zhang R; Ge X; You K; Guo Y; Guo H; Wang Y; Geng L
J Obstet Gynaecol Res; 2018 Nov; 44(11):2077-2084. PubMed ID: 30094887
[TBL] [Abstract][Full Text] [Related]
9. p16/Ki67 dual stain triage versus cytology in primary human papillomavirus-based cervical cancer screening with limited genotyping.
Trzeszcz M; Mazurec M; Jach R; Mazurec K; Kotkowska-Szeps I; Kania M; Wantuchowicz M; Wasowska J; Duczek-Polakiewicz M; Rozmus P; Streb J; Halon A
J Med Virol; 2023 Nov; 95(11):e29271. PubMed ID: 38009626
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of p16/Ki-67 dual staining in the detection of cervical precancer and cancer in China.
Zhang SK; Jia MM; Zhao DM; Wu ZN; Guo Z; Liu YL; Guo PP; Chen Q; Cao XQ; Liu SZ; Chen W; Sun XB
Cancer Epidemiol; 2019 Apr; 59():123-128. PubMed ID: 30739069
[TBL] [Abstract][Full Text] [Related]
11. p16/Ki-67 Dual Staining Is a Reliable Biomarker for Risk Stratification for Patients With Borderline/Mild Cytology in Cervical Cancer Screening.
Magkana M; Mentzelopoulou P; Magkana E; Pampanos A; Vrachnis N; Kalafati E; Daskalakis G; Domali E; Thomakos N; Rodolakis A; Anagnou NP; Pappa KI
Anticancer Res; 2022 May; 42(5):2599-2606. PubMed ID: 35489732
[TBL] [Abstract][Full Text] [Related]
12. Interpretation of p16(INK4a) /Ki-67 dual immunostaining for the triage of human papillomavirus-positive women by experts and nonexperts in cervical cytology.
Allia E; Ronco G; Coccia A; Luparia P; Macrì L; Fiorito C; Maletta F; Deambrogio C; Tunesi S; De Marco L; Gillio-Tos A; Sapino A; Ghiringhello B
Cancer Cytopathol; 2015 Apr; 123(4):212-8. PubMed ID: 25534957
[TBL] [Abstract][Full Text] [Related]
13. p16/Ki-67 dual staining has a better accuracy than human papillomavirus (HPV) testing in women with abnormal cytology under 30 years old.
Pirtea L; Secosan C; Margan M; Moleriu L; Balint O; Grigoras D; Sas I; Horhat F; Jianu A; Ilina R
Bosn J Basic Med Sci; 2019 Nov; 19(4):336-341. PubMed ID: 29924960
[TBL] [Abstract][Full Text] [Related]
14. Triaging HPV-positive women with p16/Ki-67 dual-stained cytology: Results from a sub-study nested into the ATHENA trial.
Wright TC; Behrens CM; Ranger-Moore J; Rehm S; Sharma A; Stoler MH; Ridder R
Gynecol Oncol; 2017 Jan; 144(1):51-56. PubMed ID: 28094038
[TBL] [Abstract][Full Text] [Related]
15. [Evaluation the triage performance of p16/Ki-67 dual staining for HR-HPV positive women].
Jia MM; Zhao DM; Guo Z; Wu ZN; Chen PP; Guo PP; Sun XY; Zhang SK
Zhonghua Yu Fang Yi Xue Za Zhi; 2020 Feb; 54(2):192-197. PubMed ID: 32074709
[No Abstract] [Full Text] [Related]
16. Prospective evaluation of p16/Ki-67 dual-stained cytology for managing women with abnormal Papanicolaou cytology: PALMS study results.
Bergeron C; Ikenberg H; Sideri M; Denton K; Bogers J; Schmidt D; Alameda F; Keller T; Rehm S; Ridder R;
Cancer Cytopathol; 2015 Jun; 123(6):373-81. PubMed ID: 25891096
[TBL] [Abstract][Full Text] [Related]
17. Good performance of p16/Ki-67 dual-stain cytology for detection and post-treatment surveillance of high-grade CIN/VAIN in a prospective, cross-sectional study.
Liu W; Gong J; Xu H; Zhang D; Xia N; Li H; Song K; Lv T; Chen Y; Diao Y; Jao J; Dai S; Zhao P; Yao Q
Diagn Cytopathol; 2020 Jul; 48(7):635-644. PubMed ID: 32275355
[TBL] [Abstract][Full Text] [Related]
18. Application of p16/Ki-67 dual-staining cytology in cervical cancers.
Yu L; Fei L; Liu X; Pi X; Wang L; Chen S
J Cancer; 2019; 10(12):2654-2660. PubMed ID: 31258773
[TBL] [Abstract][Full Text] [Related]
19. p16/Ki-67 dual-stained cytology used for triage in cervical cancer opportunistic screening.
Han Q; Guo H; Geng L; Wang Y
Chin J Cancer Res; 2020 Apr; 32(2):208-217. PubMed ID: 32410798
[TBL] [Abstract][Full Text] [Related]
20. [Clinical value of p16/Ki-67 immunocytochemical dual staining in cervical cancer screening].
Wang HR; Liao GD; Chen W; Qiao YL; Jiang Y
Zhonghua Zhong Liu Za Zhi; 2017 Aug; 39(8):636-640. PubMed ID: 28835090
[No Abstract] [Full Text] [Related]
[Next] [New Search]
